Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Filings
24 filings of ANTHEM since August 2025.
presentation 7, board outcome 6, transcript 6, results 3, dividend 1, credit rating 1
| Filed | Type | Subject | |
|---|---|---|---|
| 06 Nov 2026 | transcript Capex, Guidance, Results | Anthem Biosciences Limited has informed the Exchange about TranscriptAI summaryAnthem Biosciences filed the transcript of its Q2 and H1 FY27 earnings conference call held on November 04, 2026, after announcing results for the quarter and half year ended September 30, 2026. Management (CEO Ajay Bhardwaj) said Q2 FY27 consolidated revenue from operations was INR594 crores, with CRDMO revenue of INR509 crores and Specialty Ingredients of INR85 crores; Q2 EBITDA was INR330 crores (50.6% margin) and PAT was INR211 crores (32.04% margin). For H1 FY27, consolidated revenue from operations was INR1,012 crores, EBITDA INR506 crores (46.2% margin) and PAT INR331 crores (30.2% margin); net cash position as of September 30, 2026 was INR1,534 crores. CFO Gawir Baig said the commercial molecule count rose to 15 and late-stage molecules fell to 9, and that Phase 1 capex guidance of about INR1,200 crores for Unit 4 remains intact. Management said roughly 84% of revenue is international and about 85% of business is CDMO; top five customers are about 50% and top ten about 80% of business. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2026 | presentation Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed its earnings call presentation on unaudited consolidated results for the quarter and half year ended September 30, 2026; the call is scheduled for November 4, 2026 at 12:30 PM IST. Q2FY27 revenue from operations was ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn; PAT was ₹2,115 Mn, up 21.9% YoY from ₹1,734 Mn, with PAT margin of 32.4%. Q2FY27 EBITDA was ₹3,304 Mn (EBITDA margin 50.6%, up from 44.5%), including other income of ₹588.98 Mn. H1FY27 revenue from operations was ₹10,123 Mn, down 7.2% YoY from ₹10,914 Mn; H1FY27 PAT was ₹3,314 Mn, up 7.2% from ₹3,092 Mn. Net cash was ₹15,380 Mn as of September 30, 2026, versus ₹17,197 Mn as of June 30, 2026; management described growth as having accelerated in Q2FY27 and margins as the highest ever. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2026 | board outcome Results | Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026.AI summaryBoard of Anthem Biosciences Limited approved the unaudited standalone and consolidated financial results with limited review report for the quarter and half year ended September 30, 2026, at a meeting held November 3, 2026 (2.30 p.m. to 3.45 p.m.). Standalone revenue from operations for the quarter ended September 30, 2026 was Rs 5,721.08 million, against Rs 3,838.42 million in the quarter ended June 30, 2026 and Rs 5,527.03 million in the quarter ended September 30, 2025. Standalone profit for the period for the quarter ended September 30, 2026 was Rs 2,208.86 million, against Rs 1,020.09 million in the previous quarter and Rs 1,984.34 million in the year-ago quarter. Standalone revenue from operations for the half year ended September 30, 2026 was Rs 9,559.50 million, against Rs 10,913.71 million in the half year ended September 30, 2025. Standalone profit for the half year ended September 30, 2026 was Rs 3,228.95 million, against Rs 3,467.73 million in the year-ago half year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jul 2026 | transcript Capex, Guidance, Results | Anthem Biosciences Limited has informed the Exchange about TranscriptAI summaryAnthem Biosciences filed the transcript of its Q1 FY27 earnings conference call held on July 22, 2026, after announcing results for the quarter ended June 30, 2026. Management (MD and CEO Ajay Bhardwaj) reported consolidated revenue from operations of Rs. 418 crores, with CRDMO contributing Rs. 341 crores (81.5%) and Specialty Ingredients Rs. 78 crores (18.5%); EBITDA was Rs. 176 crores (39.6% margin, including other income of Rs. 25 crores), PBT Rs. 145 crores and PAT Rs. 120 crores (27.1% margin). Management said Q1 reflected timing shifts in customer deliveries, with demand described as strong and a higher concentration of deliveries expected in the latter half of the year; net cash was Rs. 1,720 crores as of June 30, 2026. Management said about 60% of the full-year order book is already in hand and that it expects growth in line with historical performance for FY27, with Unit 4 at Neo Anthem expected to be commissioned by end of next year. Management said Unit 1 utilization was about 78% and Unit 2 about 50%, while Unit 3 was at 30% to 35% in Q1 FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jul 2026 | presentation Guidance, Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed a revised earnings call presentation for the quarter ended June 30, 2026, superseding the presentation filed earlier on July 21, 2026. Q1FY27 consolidated revenue from operations was ₹4,182 Mn (down 22.6% YoY from ₹5,402 Mn); CRDMO revenue ₹3,408 Mn and Specialty Ingredients ₹774 Mn. Q1FY27 EBITDA was ₹1,755 Mn (39.6% margin, vs 38.1% a year earlier); PAT was ₹1,199 Mn (down 11.7% YoY), with a 27.1% PAT margin. Net cash stood at ₹17,197 Mn as of June 30, 2026. Management (Chairman, MD & CEO Ajay Bhardwaj) said Q1FY27 reflected timing shifts in deliveries to key customers, that underlying demand remains strong, and that a higher concentration of scheduled deliveries is expected in the latter half of the year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jul 2026 | presentation Guidance, Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed its earnings call presentation on unaudited consolidated results for the quarter ended June 30, 2026 (Q1FY27), ahead of the earnings call on July 22, 2026. Q1FY27 revenue from operations was ₹4,182 Mn, down 22.6% YoY from ₹5,402 Mn; PAT was ₹1,199 Mn, down 11.7% YoY from ₹1,358 Mn; EBITDA was ₹1,755 Mn with a 39.6% margin (vs 38.1% in Q1FY26). Net cash stood at ₹17,197 Mn as of June 30, 2026. Management (Chairman, MD & CEO Ajay Bhardwaj) said Q1FY27 results reflect timing shifts in deliveries to key customers, that underlying demand remains strong, and that a higher concentration of scheduled deliveries is expected in the latter half of the year. Management said it remains committed to sustaining revenue growth aligned with long-term historical performance and cited year-on-year improvement in EBITDA and PAT margins. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jul 2026 | board outcome Results | Anthem Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard of Anthem Biosciences Limited approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 at a meeting held July 21, 2026 (1:45 p.m. to 3:35 p.m.). Standalone revenue from operations for Q1 FY27 was Rs 3,838.42 million, against Rs 5,825.01 million in the previous quarter (March 31, 2026) and Rs 5,380.11 million in the year-ago quarter (June 30, 2025). Standalone profit for the period was Rs 1,020.09 million, against Rs 2,116.65 million in the previous quarter and Rs 1,483.40 million in the year-ago quarter; basic EPS was Rs 1.81 (not annualised). The statutory auditors, K. P. Rao & Co., issued a limited review report with an unmodified conclusion on the standalone results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Jul 2026 | credit rating Rating | Anthem Biosciences Limited has informed the Exchange about Credit RatingAI summaryAnthem Biosciences Limited filed an intimation under SEBI LODR Regulation 30 that ICRA Limited has revised its credit ratings on the company's bank facilities. ICRA upgraded the Long Term/Short Term fund based working capital (Rs. 175 crore) to [ICRA]AA (Stable) from [ICRA]AA- (Positive), with the short term rating [ICRA]A1+ reaffirmed. ICRA upgraded the Long Term fund based term loan (Rs. 67.50 crore) to [ICRA]AA (Stable) from [ICRA]AA- (Positive) and assigned the rating for an enhanced limit. Non-fund based short term limit (Rs. 10 crore) was assigned [ICRA]A1+ for an enhanced limit; unallocated limits (Rs. 23 crore) were upgraded to [ICRA]AA (Stable) and [ICRA]A1+ reaffirmed. Total rated amount is Rs. 275.50 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Jul 2026 | results Results | The Exchange had sought clarification from Anthem Biosciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the ComAI summaryAnthem Biosciences Limited filed a clarification dated June 23, 2026 responding to NSE's email of June 17, 2026 on discrepancies in its financial results for the quarter and year ended March 31, 2026 (submitted May 19, 2026). The company says FY2025-26 profit after tax of INR 5,917.92 million in the PDF financial statements matches the XBRL filing, so there is no PAT mismatch. The omission of consolidated EPS from the XBRL filing was described as an inadvertent clerical error. The company said it will submit a revised XBRL filing including consolidated EPS after the clarification letter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Jun 2026 | results | The Exchange has sought clarification from Anthem Biosciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Com | |
| 22 May 2026 | transcript Capex, Guidance, Results | Anthem Biosciences Limited has informed the Exchange about TranscriptAI summaryAnthem Biosciences filed the transcript of its Q4 & FY26 earnings conference call held May 20, 2026, after announcing audited results for the quarter and year ended March 31, 2026. FY26 consolidated revenue from operations was Rs. 2,124 crores (CRDMO Rs. 1,773 crores, up 18%; specialty ingredients Rs. 352 crores); total revenue including other income was Rs. 2,280 crores; EBITDA Rs. 990 crores (43.4% margin); PAT Rs. 592 crores. Q4 FY26 consolidated revenue from operations was Rs. 611 crores, up 26% YoY, the highest quarterly revenue to date; Q4 PAT was Rs. 190 crores. Management (Ajay Bhardwaj, CEO) said destocking has mostly passed and restocking is now expected; management declined to give FY27 or FY28 guidance but aims to deliver ~20% growth over the long term. Management said capex in Unit 4 Phase 1 is about Rs. 1,200 crores over FY27 and FY28, with roughly Rs. 700 crores expected in FY27 and about Rs. 500 crores thereafter; capacity is not seen as a constraint until Unit 4 comes up. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | dividend Dividend / buy-back, Management change, Results | Anthem Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 19, 2026, recommended Final Dividend of Rs. 2 per equity share.AI summaryAnthem Biosciences Limited's board met on May 19, 2026 and approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from K. P. Rao & Co. The board recommended a final dividend of INR 2.00 per equity share (face value INR 2.00), subject to shareholder approval at the AGM; record date is Friday, June 26, 2026. The 20th AGM is convened for Wednesday, July 22, 2026. The board approved allotment of 14,81,250 equity shares to employees under the Anthem Employee Stock Option Plan 2024, raising paid-up capital to INR 1,12,63,90,202. The board approved re-appointment of M/s. BPU & Co. as internal auditor for FY 2026-27, recommended continuation of Mr. Ravikant Uppal as Non-Executive Independent Director (on attaining age 75 on May 9, 2027), and recommended re-appointment of Mr. Ravindra Chandrappa as Whole Time Director. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | presentation Guidance, Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed its earnings call presentation on the audited consolidated results for the quarter and year ended March 31, 2026; the earnings call is scheduled for May 20, 2026, at 11:00 AM IST. Q4FY26 revenue from operations was Rs. 6,109 Mn, up 26.4% YoY (CRDMO Rs. 5,128 Mn; Specialty Ingredients Rs. 981 Mn); Q4FY26 PAT was Rs. 1,898 Mn, up 129.8% YoY, with EBITDA margin of 48.1%. FY26 revenue from operations was Rs. 21,243 Mn, up 15.2% YoY; FY26 EBITDA was Rs. 9,896 Mn, up 30.8%, and PAT was Rs. 5,918 Mn, up 31.1%. FY26 results include an exceptional item of Rs. 244 Mn arising from the new Labour Codes notified on November 21, 2025. Management (Chairman, MD and CEO Ajay Bhardwaj) said the company ended FY2025-26 on a strong note with its highest revenue quarter ever and aims to build one of the most agile, science-led, and future-ready CRDMO platforms in the world. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | board outcome Dividend / buy-back, Management change, Results | Anthem Biosciences Limited has submitted to the Exchange, the outcome of the Board Meeting dated May 19, 2026 declaring the financial results for the quarter and the financial year ended March 31, 2026 along with other matters.AI summaryBoard of Anthem Biosciences Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from K. P. Rao & Co. Board recommended a final dividend of INR 2.00 per equity share (face value INR 2.00) for FY2025-26, subject to shareholder approval at the AGM; record date is Friday, June 26, 2026. Board approved convening the 20th AGM on Wednesday, July 22, 2026. Board approved allotment of 14,81,250 equity shares under the Anthem Employee Stock Option Plan 2024, raising paid-up capital to INR 1,12,63,90,202. Board approved re-appointment of BPU & Co. as internal auditor for FY2026-27, and recommended continuation of Mr. Ravikant Uppal as Non-Executive Independent Director (upon reaching age 75 on May 09, 2027) and re-appointment of Mr. Ravindra Chandrappa, Whole Time Director, retiring by rotation, both subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | transcript Guidance, Results | Anthem Biosciences Limited has informed the Exchange about TranscriptAI summaryAnthem Biosciences filed the transcript of its Q3 & 9M FY26 earnings conference call held on February 05, 2026, following its results for the quarter and nine months ended December 31, 2025. Management (CEO Ajay Bhardwaj) reported 9M FY26 consolidated revenue from operations of Rs. 1,513 crore (CRDMO Rs. 1,260 crore; specialty ingredients Rs. 254 crore), EBITDA of Rs. 671 crore (41.5% margin) and PAT of Rs. 402 crore after a Rs. 25.4 crore exceptional item for new Labour Codes. For Q3 FY26, consolidated revenue from operations was Rs. 423 crore, EBITDA Rs. 191 crore (41.8%) and PAT Rs. 93 crore (20.3% margin). CFO Gawir Baig said management still expects FY26 revenue growth of about 15% to 16% and EBITDA and PAT growth of above 20%, and that Q4 is typically the strongest quarter. Management said the Q3 revenue slowdown reflected a high base and customer destocking, and that it expects growth to resume in FY27, though it gave no firm FY27 numbers. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | presentation Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed its earnings call presentation on unaudited consolidated results for the quarter and nine months ended December 31, 2025. Q3FY26 revenue from operations was ₹4,232 Mn, down 15.0% YoY from ₹4,978 Mn; EBITDA was ₹1,907 Mn (41.8% margin) and profit after tax was ₹928 Mn, down 25.3% YoY from ₹1,243 Mn. Q3FY26 PBT after exceptional items included a ₹254 Mn exceptional charge from the four Labour Codes notified on November 21, 2025, mainly from changes in wage definition and gratuity provisions. 9MFY26 revenue from operations was ₹15,134 Mn, up 11.2% YoY; 9MFY26 PAT was ₹4,020 Mn, up 9.1% YoY, and net cash was ₹12,312 Mn as of December 31, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | board outcome Capex, Results | Anthem Biosciences Limited has submitted to the Exchange, the financial results for the quarter and nine months ended December 31, 2025.AI summaryBoard of Anthem Biosciences Limited met on February 05, 2026 (11:40 a.m. to 12:55 p.m.) and approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with the statutory auditors' limited review report. The Board approved allotment of 1,03,800 equity shares of face value Rs. 2 each under the Anthem Employee Stock Option Plan 2024, at an exercise price of Rs. 100.75 per share. Paid-up equity share capital rises from Rs. 1,12,32,20,102 (56,16,10,051 shares) to Rs. 1,12,34,27,702 (56,17,13,851 shares) after the allotment. The filing does not state the revenue or profit figures for the quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | transcript Capex, Guidance, Results | Anthem Biosciences Limited has informed the Exchange about TranscriptAI summaryAnthem Biosciences filed the transcript of its Q2 & H1 FY26 earnings conference call held on November 10, 2025, following its unaudited results for the quarter and half year ended September 30, 2025. Management said H1 FY26 consolidated revenue from operations was Rs. 1,090 Cr (CRDMO Rs. 926 Cr, specialty ingredients Rs. 163 Cr), EBITDA Rs. 480 Cr at a 41.4% margin, and PAT Rs. 309 Cr at a 26.6% margin, with cash in hand of Rs. 993 Cr as of September 30, 2025. Management attributed the H1 specialty ingredients decline to capacity being diverted to the busier CRDMO business, and expects specialty ingredients to make up the decline for the rest of the year. Management said CP 6 and CP 7 (about Rs. 182 Cr capex, about 130 kilolitres) can generate about Rs. 300 Cr+ revenue, and Unit-IV (green-field, about Rs. 1,000 Cr investment) is targeted for commissioning in about two years. Management said approved commercial molecules rose from 10 at listing to 14, with late-phase molecules down to 6, and timing of further approvals is not visible to management. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Nov 2025 | presentation Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed its earnings call presentation on the unaudited consolidated results for the quarter and half year ended September 30, 2025, with the earnings call scheduled for November 10, 2025. Q2FY26 revenue from operations was ₹5,500 Mn (up 4.8% YoY); CRDMO revenue ₹4,719 Mn (up 8.5%) and Specialty Ingredients ₹781 Mn (down 13.1%). Q2FY26 EBITDA was ₹2,661 Mn with a 44.5% margin (Q2FY25: ₹2,231 Mn, 40.4%); PAT was ₹1,734 Mn (up 7.1% YoY), with PAT margin of 29.0%. H1FY26 revenue from operations was ₹10,902 Mn (up 26.3%) and PAT was ₹3,092 Mn (up 26.6%); net cash stood at ₹9,934 Mn as of September 30, 2025. Management described Q2FY26 returns as robust, citing ROE of 26.9% and post-tax ROCE of 36.2%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Nov 2025 | board outcome Results | Anthem Biosciences Limited has submitted to the Exchange, the financial results for the quarter and half year ended September 30, 2025.AI summaryAnthem Biosciences Limited board meeting held November 8, 2025 approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with Limited Review Report from statutory auditors. Standalone revenue from operations for Q2 FY26 (quarter ended Sept 30, 2025) was Rs 5,522.26 million, against Rs 5,248.63 million a year earlier. Standalone profit for the period for Q2 FY26 was Rs 1,984.34 million, against Rs 1,702.96 million a year earlier. Standalone revenue from operations for the half year ended Sept 30, 2025 was Rs 10,902.36 million; half-year profit for the period was Rs 3,467.73 million. Basic EPS for Q2 FY26 (not annualised) was Rs 3.54. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Sep 2025 | results | The Exchange has sought clarification from Anthem Biosciences Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Com | |
| 18 Aug 2025 | transcript Capex, Guidance, Results | Anthem Biosciences Limited has informed the Exchange about TranscriptAI summaryAnthem Biosciences filed the transcript of its Q1 FY26 earnings conference call held on August 14, 2025, after announcing results for the quarter ended June 30, 2025. Ajay Bhardwaj (MD and CEO) said consolidated revenue from operations was INR540 crores, with CRDMO revenue of INR452.7 crores and speciality ingredients of INR87.5 crores; EBITDA was INR214.3 crores (38% margin) and PAT margin was 24%. Management said the quarter was exceptional, driven by higher demand for commercial products, and that the outlook remains about 20% year-on-year growth for FY26 over FY25. Management said custom synthesis capacity utilisation is about 70% and fermentation about 50%, with unit 2 and unit 3 expansion (about INR150 crores capital commitment) to be completed and unit 4 at an early planning stage. Net cash was INR784.8 crores as of June 30, 2025, and management said it will fund the capacity expansion largely from this treasury. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2025 | presentation Capex, Results | Anthem Biosciences Limited has informed the Exchange about Investor PresentationAI summaryAnthem Biosciences filed its earnings call presentation on unaudited consolidated results for the quarter ended June 30, 2025 (Q1FY26). Q1FY26 revenue from operations was ₹5,402 Mn, up 59.5% YoY from ₹3,386 Mn; CRDMO revenue ₹4,527 Mn and Specialty Ingredients ₹875 Mn. EBITDA was ₹2,143 Mn (38.1% margin) and PAT was ₹1,358 Mn (24.1% PAT margin), up 64.8% YoY; net cash stood at ₹7,848 Mn as of June 30, 2025. Management reported that 54 kL of custom synthesis capacity at Unit II (Harohalli) was completed and commercial operations commenced, and that Unit III (NeoAnthem) operations commenced in a phased manner, including a 16 kL peptide facility and a 2.5 kL high-potent facility. Management also said construction has started on a new greenfield facility (Unit IV) on a 30-acre site at Harohalli, Bangalore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2025 | board outcome Management change, Results | Anthem Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryAnthem Biosciences Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, along with the statutory auditors' limited review report (K. P. Rao & Co.), at a meeting held August 13, 2025. The Audit Committee reviewed and recommended the quarterly results to the Board on August 12, 2025. The Board approved the change in designation of Mr. Ravi Kalla from Senior General Manager – Information Technology to Chief Information Officer, classified as Senior Management Personnel, effective August 13, 2025. Mr. Ravi Kalla has 25 years of experience in information technology, process automation, cyber security and GxP systems, and has been associated with the company since inception. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.